Fisetin

Mechanism of Action

Fisetin is a naturally occurring flavonoid that demonstrates multiple therapeutic mechanisms at the molecular and cellular level, though the evidence base is still developing.

Anti-inflammatory and Neuroprotective Pathways

Research indicates that fisetin modulates key neuroinflammatory, oxidative stress, and autophagy pathways in neurodegenerative disorders. In laboratory studies using amyotrophic lateral sclerosis (ALS) cell models, fisetin prevented deterioration of cellular functions in cells containing specific protein variants (G262R and P438L of SQSTM1), suggesting it may help maintain cellular integrity under pathological conditions.

Hepatoprotective Mechanisms

In mouse models of liver injury, fisetin appears to work through two primary molecular pathways:

• TGF-β1/Smad3 pathway modulation: This pathway is involved in fibrosis and tissue scarring
• p53/Bax/Bcl-2 pathway regulation: These proteins control programmed cell death (apoptosis)

The modulation of these pathways suggests fisetin may help protect liver cells from toxic damage and prevent excessive cell death.

Cancer Cell Effects

Laboratory studies suggest fisetin may affect cancer cell proliferation through multiple mechanisms:

• Interference with cell cycle progression leading to growth arrest
• Potential modulation of microRNA (miRNA) and long non-coding RNA (lncRNA) expression profiles
• When formulated as glucose-capped silver nanoparticles, it appears to disrupt protein expression patterns in breast cancer cells

Senolytic Properties

Emerging research suggests fisetin may have senolytic effects, meaning it could selectively target and eliminate senescent (aged and dysfunctional) cells. This mechanism is being investigated for its potential role in addressing age-related conditions including frailty and ovarian aging, though the specific molecular pathways involved require further clarification.

Limitations and Clinical Translation

While laboratory studies show promising molecular mechanisms, the clinical evidence remains limited. Several clinical trials investigating fisetin for conditions including COVID-19, frailty, and osteoarthritis have been terminated, withdrawn, or suspended, indicating challenges in translating laboratory findings to human applications.

Disclaimer: This information is for educational purposes only and should not be used as medical advice. Consult healthcare providers before using fisetin or any supplement for therapeutic purposes.

Fisetin, a naturally occurring flavonoid, is being investigated across several therapeutic areas, though clinical evidence remains limited with most research still in early phases.

Aging and Cellular Senescence

The most advanced clinical research focuses on fisetin's potential as a senolytic agent. A Phase 2 trial (NCT03430037) is currently enrolling older women to evaluate fisetin's effects on frailty, inflammation, and related age-associated measures. This builds on laboratory evidence suggesting fisetin may help clear senescent cells that accumulate with aging.

A COVID-19 pilot study in nursing home residents (NCT04537299) was terminated, limiting insights into fisetin's potential protective effects in vulnerable older populations during viral infections.

Osteoarthritis and Joint Health

Several planned studies aimed to investigate fisetin for osteoarthritis, though these have faced implementation challenges. Trials examining fisetin's effects on knee osteoarthritis pain and function (NCT05482672, NCT05505747) and its potential senolytic effects in osteoarthritis (NCT05276895) have been withdrawn or suspended. The rationale for these studies stems from preclinical evidence suggesting fisetin may reduce joint inflammation and cartilage degradation.

Cancer Research

Laboratory studies are exploring fisetin's anti-cancer properties across multiple cancer types. Recent research has investigated:

• Lung cancer: Combination therapies using fisetin with other compounds in nanoparticle delivery systems for non-small cell lung cancer
• Breast cancer: Studies examining how fisetin-containing nanoparticles may arrest cancer cell proliferation
• Colorectal cancer: Investigation of fisetin among other plant-derived polyphenols for potential therapeutic effects

However, no clinical trials in cancer patients have been identified in the current evidence.

Neurological Conditions

Preclinical research suggests fisetin may benefit neurodegenerative disorders through multiple mechanisms including reducing neuroinflammation, oxidative stress, and supporting cellular cleanup processes. Studies have specifically examined potential applications in amyotrophic lateral sclerosis (ALS), though clinical trials in neurological conditions are not yet underway.

Liver Protection

Laboratory studies indicate fisetin may protect against liver injury through modulation of specific cellular pathways, though clinical applications have not been tested.

Current Limitations

The clinical evidence for fisetin remains quite limited. Most ongoing or planned human studies are in early phases or have faced implementation challenges. While preclinical research shows promise across multiple conditions, robust clinical data demonstrating efficacy and optimal dosing in humans is still needed.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers before using fisetin or any supplement for medical conditions.

Current Evidence Limitations

The safety profile of fisetin is not well-established through rigorous human clinical trials. Most available evidence comes from preclinical animal studies and in vitro research, with limited human safety data from ongoing or completed clinical trials.

Clinical Trial Safety Experience

Available clinical trial data is limited:

• One COVID-19 trial in older adults (NCT04537299) was terminated, though termination reasons are not specified in the available evidence
• One ongoing trial examining frailty in older women (NCT03430037) is currently enrolling by invitation
• Several other trials investigating fisetin have been withdrawn or suspended

Known Side Effects

Evidence for specific side effects in humans is thin. The available research does not provide comprehensive safety profiles or systematic adverse event reporting from human studies.

Contraindications and Precautions

Based on limited available evidence, specific contraindications have not been well-established. However, given the lack of robust human safety data, caution is warranted in:

• Pregnancy and breastfeeding (no safety data available)
• Children (no pediatric safety studies identified)
• Individuals with liver disease (though one study showed potential hepatoprotective effects in mice, human data is lacking)

Drug Interactions

The available evidence does not provide information about potential drug interactions with fisetin. This represents a significant knowledge gap that requires further investigation.

Populations That Should Exercise Caution

Given the limited human safety data, the following populations should exercise particular caution:

• Individuals taking multiple medications (unknown interaction potential)
• Those with chronic medical conditions
• Patients scheduled for surgery (unknown effects on bleeding or anesthesia)

Evidence Quality Statement

The safety evidence for fisetin is notably thin, consisting primarily of preclinical studies with minimal human clinical data. Most research has focused on potential therapeutic effects rather than comprehensive safety evaluation. More rigorous human safety studies are needed to establish a complete safety profile.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before using fisetin, especially if you have medical conditions or take other medications.

Research Papers and Clinical Trials

Recent preclinical research on fisetin has explored its potential therapeutic applications across several disease areas, though human clinical evidence remains limited.

Preclinical Research

Laboratory studies have investigated fisetin's effects in neurodegenerative diseases, with one 2026 study examining its protective effects in cellular models of amyotrophic lateral sclerosis (ALS). The research used SH-SY5Y cells with specific genetic variants (G262R and P438L of SQSTM1) associated with ALS, though specific sample sizes and detailed methodologies are not provided in the available abstracts.

Cancer research has shown activity across multiple tumor types. A 2026 study developed nanostructured lipid carriers combining fisetin with flavokawain A for non-small cell lung cancer treatment, while another investigated glucose-capped fisetin silver nanoparticles in breast cancer cell models. The breast cancer study included proteomic profiling and analysis of RNA regulatory mechanisms, but sample sizes are not specified in available information.

Liver protection studies have examined fisetin's effects against chemical-induced injury. A 2026 mouse study investigated fisetin's protective effects against carbon tetrachloride (CCl4)-induced liver damage, focusing on TGF-β1/Smad3 and p53/Bax/Bcl-2 signaling pathways, though the number of animals studied is not reported.

Additional research has explored fisetin's role as a senotherapeutic agent (targeting cellular aging) and its anti-inflammatory properties, particularly in the context of neurodegeneration and ovarian aging.

Clinical Trials

Human clinical research on fisetin remains very limited. Five registered clinical trials have been identified, but most have encountered significant challenges:

• COVID-19 study (NCT04537299): A Phase 2 pilot study investigating fisetin in older adults in nursing homes with COVID-19 was terminated, with no results reported.

• Frailty study (NCT03430037): A Phase 2 trial examining fisetin's effects on frailty and inflammation in older women is currently enrolling participants by invitation only.

• Three additional trials investigating fisetin in knee osteoarthritis, meniscus repair, and general osteoarthritis have been either withdrawn or suspended before completion.

The limited clinical data means that while laboratory studies suggest potential therapeutic benefits, human efficacy and safety data for fisetin remain insufficient to draw clinical conclusions.

Note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for medical decisions.

Dosing/Administration Protocols for Fisetin

The available clinical trial evidence for fisetin dosing protocols is extremely limited. The literature search reveals only a few active or completed clinical trials investigating fisetin in humans, with most studies being preclinical research.

Current Clinical Trial Evidence

From the clinical trials identified:

• NCT03430037: A Phase 2 trial examining fisetin for frailty and inflammation in older women (currently enrolling by invitation)
• NCT04537299: A terminated Phase 2 pilot study investigating fisetin in COVID-19 patients in nursing homes

Unfortunately, specific dosing information, administration routes, or treatment duration protocols are not provided in the available trial registry data.

Research Context

The majority of published research on fisetin consists of:

• In vitro cell culture studies using various concentrations
• Animal studies with different dosing regimens
• Nanoparticle formulation research for drug delivery optimization

However, these preclinical dosing approaches cannot be directly translated to human clinical protocols without proper safety and pharmacokinetic studies.

Evidence Limitations

The current evidence base for established human dosing protocols for fisetin is insufficient. While preclinical research suggests potential therapeutic benefits in neurodegenerative disorders, cancer, and aging-related conditions, standardized clinical dosing guidelines have not been established through completed human trials.

---

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Any use of fisetin should be discussed with a qualified healthcare provider, particularly given the limited clinical trial data available for human dosing protocols.

Outcomes

The evidence for measurable outcomes with fisetin is extremely limited, consisting primarily of preclinical laboratory studies with minimal human clinical trial data.

Preclinical Findings:

Laboratory studies suggest potential benefits across several conditions, though these are early-stage investigations:

• Liver protection: In mouse models of carbon tetrachloride-induced liver injury, fisetin demonstrated protective effects through modulation of TGF-β1/Smad3 and p53/Bax/Bcl-2 pathways
• Neurological conditions: Cell culture studies indicate fisetin may prevent deterioration of cellular functions in specific genetic variants associated with amyotrophic lateral sclerosis (ALS)
• Cancer research: Multiple studies explore fisetin's effects on cancer cells, including investigations of nanoparticle delivery systems and combination therapies, though specific outcome measures are not detailed in the available evidence

Clinical Trial Evidence:

Human clinical data is notably sparse:

• One pilot study investigating fisetin for COVID-19 in older nursing home residents was terminated (specific outcomes not reported)
• One ongoing Phase 2 trial is examining fisetin for frailty and inflammation in older women, but results are not yet available
• Several other registered trials examining fisetin for osteoarthritis, meniscus repair, and other conditions have been withdrawn or suspended

Strength of Evidence:

The evidence base is currently very weak for clinical outcomes. While preclinical studies show mechanistic activity across multiple pathways (neuroinflammation, oxidative stress, autophagy), these laboratory findings have not been translated into demonstrated clinical benefits. The lack of completed human trials means there are no validated biomarker changes, symptom improvements, or other measurable clinical outcomes to report.

This information is for educational purposes only and does not constitute medical advice. Consult healthcare providers before considering any therapeutic interventions.